Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA.
Acad Emerg Med. 2023 Dec;30(12):1223-1236. doi: 10.1111/acem.14798. Epub 2023 Sep 12.
Historical cardiac troponin (cTn) elevation is commonly interpreted as lessening the significance of current cTn elevations at presentation for acute heart failure (AHF). Evidence for this practice is lacking. Our objective was to determine the incremental prognostic significance of historical cTn elevation compared to cTn elevation and ischemic heart disease (IHD) history at presentation for AHF.
A total of 341 AHF patients were prospectively enrolled at five sites. The composite primary outcome was death/cardiopulmonary resuscitation, mechanical cardiac support, intubation, new/emergent dialysis, and/or acute myocardial infarction (AMI)/percutaneous coronary intervention (PCI)/coronary artery bypass grafting (CABG) at 90 days. Secondary outcomes were 30-day AMI/PCI/CABG and in-hospital AMI. Logistic regression compared outcomes versus initial emergency department (ED) cTn, the most recent electronic medical record cTn, estimated glomerular filtration rate, age, left ventricular ejection fraction, and IHD history (positive, negative by prior coronary workup, or unknown/no prior workup).
Elevated cTn occurred in 163 (49%) patients, 80 (23%) experienced the primary outcome, and 29 had AMI (9%). cTn elevation at ED presentation, adjusted for historical cTn and other covariates, was associated with the primary outcome (adjusted odds ratio [aOR] 2.39, 95% confidence interval [CI] 1.30-4.38), 30-day AMI/PCI/CABG, and in-hospital AMI. Historical cTn elevation was associated with greater odds of the primary outcome when IHD history was unknown at ED presentation (aOR 5.27, 95% CI 1.24-21.40) and did not alter odds of the outcome with known positive (aOR 0.74, 95% CI 0.33-1.70) or negative IHD history (aOR 0.79, 95% CI 0.26-2.40). Nevertheless, patients with elevated ED cTn were more likely to be discharged if historical cTn was also elevated (78% vs. 32%, p = 0.025).
Historical cTn elevation in AHF patients is a harbinger of worse outcomes for patients who have not had a prior IHD workup and should prompt evaluation for underlying ischemia rather than reassurance for discharge. With known IHD history, historical cTn elevation was neither reassuring nor detrimental, failing to add incremental prognostic value to current cTn elevation alone.
历史上的心肌肌钙蛋白(cTn)升高通常被解释为降低了急性心力衰竭(AHF)患者当前 cTn 升高的重要性。但缺乏相关证据。我们的目的是确定与当前 cTn 升高和就诊时的缺血性心脏病(IHD)病史相比,历史上的 cTn 升高对 AHF 的预后的增量预测价值。
共前瞻性纳入了 5 个地点的 341 例 AHF 患者。复合主要结局是 90 天内死亡/心肺复苏、机械心脏支持、插管、新/紧急透析和/或急性心肌梗死(AMI)/经皮冠状动脉介入治疗(PCI)/冠状动脉旁路移植术(CABG)。次要结局是 30 天内 AMI/PCI/CABG 和院内 AMI。逻辑回归比较了初始急诊(ED)cTn、最近的电子病历 cTn、估计肾小球滤过率、年龄、左心室射血分数和 IHD 病史(阳性、通过之前的冠状动脉检查为阴性或未知/无先前检查)与结果的关系。
163 例(49%)患者的 cTn 升高,80 例(23%)发生主要结局,29 例发生 AMI(9%)。在调整历史 cTn 和其他协变量后,ED 就诊时的 cTn 升高与主要结局(调整后的优势比[aOR] 2.39,95%置信区间[CI] 1.30-4.38)、30 天内 AMI/PCI/CABG 和院内 AMI 相关。当 ED 就诊时 IHD 病史未知时,历史 cTn 升高与更高的主要结局风险相关(aOR 5.27,95%CI 1.24-21.40),但与已知阳性 IHD 病史(aOR 0.74,95%CI 0.33-1.70)或阴性 IHD 病史(aOR 0.79,95%CI 0.26-2.40)无关。然而,如果 ED cTn 升高,患者更有可能出院(78%比 32%,p=0.025)。
在未进行先前 IHD 检查的 AHF 患者中,历史 cTn 升高是预后不良的标志,应提示评估潜在的缺血,而不是为出院提供保证。对于已知的 IHD 病史,历史 cTn 升高既不能保证也不能损害,无法为当前 cTn 升高单独提供额外的预后价值。